Investigator's Brochure (IB) Table
Drugs
| Drug Name Sort descending | Drug Company | IB Date | Risk List Available? |
|---|---|---|---|
| ABT-267, ABT 333, ABT-450 and Ritonavir | AbbVie | June 2017 | |
| Bedaquiline (TMC207) | Janssen Research & Development | October 2025 | |
| Delamanid (OPC-67683) | Otsuka | August 2024 | |
| Dolutegravir (GSK1349572) | ViiV Healthcare | October 2025 | |
| Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) | Gilead Sciences | December 2016 | YES |
| Glecaprevir/Pibrentasvir | AbbVie | December 2025 | |
| GSK1265744 (Cabotegravir) | ViiV Healthcare | January 2026 | |
| Pretomanid (PA-824) | Global Alliance for TB Drug Development (TB Alliance) | December 2025 | |
| Quercefit (Quercetin Phospholipid) | Indena | February 2025 | |
| Remdesivir (Veklury) | Gilead Sciences | June 2021 | |
| Rilpivirine (TMC278, Edurant) | Janssen Research & Development | June 2025 | |
| Sutezolid | Global Alliance for TB Drug Development (TB Alliance) | April 2025 | |
| TBI-223 | Global Alliance for TB Drug Development (TB Alliance) | October 2023 | |
| Tenofovir | Conrad | November 2024 | |
| Tenofovir Disoproxil Fumarate/Emtricitabine/Levonorgestrel/ Ethinyl estradiol (Ahana) | Viatris | August 2024 | |
| Vorinostat (Zolinza) | Merck | August 2013 |
Vaccines
| Vaccine Name Sort descending | Vaccine Company | IB Date | Risk List Available? |
|---|---|---|---|
| HIV-1 Adenovirus Type 4-Vectored (A549 cells) Vaccines (Ad4-Env150KN and Ad4-Env145NFL) | VRC/NIAID/NIH | July 2021 | |
| HxB2.WT.Core-C4b, Adjuvanted | DAIDS/NIAID/NIH | October 2024 | |
| ID93 + GLA Adjuvant Vaccine | AAHI | May 2025 | |
| mRNA-1574 Trimer Vaccines | DAIDS/NIAID/NIH | November 2024 | |
| mRNA-1645-eODGT8 and mRNA-1645-CoreG28v2 | Moderna | October 2024 | |
| mRNA-1645-N332GT5 | Moderna | October 2024 | |
| MTBVAC | Biofabri | July 2024 | |
| MVA.tHIVconsv3 Vaccine | University of Oxford | May 2025 | |
| MVA.tHIVconsv4 Vaccine | University of Oxford | May 2025 | |
| N-803 | Altor BioScience (ImmunityBio) | December 2023 | |
| N332-GT5 gp140, Adjuvanted with SMNP | DAIDS/NIAID/NIH | July 2025 | |
| PGDM1400LS (VRC-HIVMAB0112-00-AB) - New | DAIDS/NIAID/NIH | April 2026 | |
| PGT121 | Beth Israel Deaconess Medical Center | September 2020 | |
| PGT121.414.LS (VRC-HIVMAB0107-00-AB) - New | VCMP/NIAID/NIH | April 2026 | |
| Poly-ICLC (Hiltonol) | Oncovir, Inc. | January 2025 | |
| Poly-ICLC (Hiltonol) | Oncovir, Inc. | July 2025 | |
| Selgantolimod (GS-9688) | Gilead | December 2024 | |
| Selgantolimod (GS-9688) | Gilead | January 2026 | |
| UVAX-1197 / UVAX-1107 | Uvax Bio LLC | January 2025 | |
| V3G CH848 Pr-NP1, Adjuvanted V3G CH848 mRNA-Tr2 and DV702B2-RNA | VRC/NIAID/NIH | January 2026 |